

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA158; Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (including a review of TA67)

This guidance was issued September 2008 with a review date of September 2011.

Background

At the GE meeting of 20 September 2011 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	The guidance should be transferred to the 'static guidance list'. ¹ That we consult on this proposal. That we add to the NICE TA158 webpage the hyperlink to the current Chief Medical Officer advice on influenza.
Rationale for selecting this proposal	The new clinical evidence that has been published since TA158 was issued is consistent with the conclusions by the Appraisal Committee on the clinical effectiveness of oseltamivir and zanamivir. There have been no relevant changes to the price of oseltamivir, zanamivir or amantadine, and no information is available about any changes to the marketing authorisation or any relevant new or ongoing trials of the effectiveness of these drugs. Based on this information it is proposed that the guidance is placed on the static list.

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

¹ Guidance is placed on the static list when it is clear that there is no new research available that would have any material effect on the current guidance. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

Recommendation post consultation:	The guidance should be transferred to the 'static guidance list' and a hyperlink to the current Chief Medical Officer advice on influenza should be added to the NICE TA158 webpage.
--	--

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Healthcare Improvement Scotland	No comment	Healthcare Improvement Scotland has no comment to make on the proposal to move the above guidance to the static list, and we await confirmation of the proposal.	Comment noted
Heart Care Partnership	No comment	I know nothing about these drugs so I am unable to respond.	Comment noted
British Thoracic Society	Agree	This is to confirm that the British Thoracic Society is in agreement with the proposal to move the guidance to the static list.	Comment noted
Royal College of Nursing	No comment	Nurses who care for people with influenza were invited to comment on the proposal regarding the review of the above guidance. There are no comments to make on behalf of the Royal College of Nursing on the proposal to move the guidance to the static list.	Comment noted

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Department of Health		<p>I have received the following comments from policy colleagues in the Department of Health's immunisation branch:</p> <p>"The NICE guidance on antivirals does not cover their use during pregnancy.</p> <p>However, as pregnancy is now considered a risk category by JCVI for the purposes of vaccination (see sources below), use of antivirals in pregnancy should be covered by the NICE guidance. The summary of product characteristics (SPC) for zanamivir is very cautious about use in pregnancy but the oseltamivir SPC less so.</p> <p>Influenza Green Book chapter: 2011 CMO letter on influenza: Similarly, NICE guidance on TA168 - treatment using oseltamivir and zanamivir - should also cover use in pregnancy".</p>	<p>Comment noted.</p> <p>Pregnant women are considered at risk according to the Chief Medical Officer's advice on influenza. The list of at risk groups will be updated periodically by the Chief Medical Officer. The recommendations in TA 158 refer to this. Also, a hyperlink to the current Chief Medical Officer advice on influenza will be added to the NICE TA158 webpage.</p>
Medicines and Healthcare products Regulatory Agency	No comment	We are not aware of any information that affects this proposal.	Comment noted
Royal College of Physicians	Agree	We endorse the response of the British Thoracic Society to the proposal.	Comment noted

No response received from:

<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none">• Alliance Pharmaceuticals (amantadine)• GlaxoSmithKline (zanamivir)• Roche Products (oseltamivir) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none">• Action Heart• Afiya Trust• African HIV Policy Network• Asthma UK• AVERT• Black Health Agency• Brain and Spine Foundation• British Cardiac Patients Association• British Kidney Patient Association• British Liver Trust• British Lung Foundation• Cancer Black Care• Cancer Equality• Cancer52• CANCERactive• Children's Liver Disease Foundation• Chinese National Healthy Living Centre• Counsel and Care• Diabetes Research & Wellness Foundation• Diabetes UK• Equalities National Council• European Federation of Allergy and Airway Diseases Patients Association	<p><u>General</u></p> <ul style="list-style-type: none">• Board of Community Health Councils in Wales• British National Formulary• Care Quality Commission• Commissioning Support Appraisals Service• Department of Health, Social Services and Public Safety for Northern Ireland• Diabetes UK Cymru• National Association of Primary Care• National Pharmacy Association• NHS Alliance• NHS Commercial Medicines Unit• NHS Confederation• Public Health Wales NHS Trust• Scottish Medicines Consortium• Welsh Kidney Patients Association <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none">• Alliance Pharmaceuticals (amantadine)• GlaxoSmithKline (zanamivir)• Roche Pharmaceuticals (oseltamivir) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none">• Cochrane Metabolic & Endocrine Disorders Group• Cochrane Renal Group• Diabetes Foundation• Heart Disease and Diabetes Research Trust• Institute of Cancer Research• Juvenile Diabetes Research Foundation
---	---

- Faculty of Public Health
- HEART UK
- Helen Rollason Heal Cancer Charity
- Juvenile Diabetes Research Association
- Kidney Alliance
- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie Cancer Care
- Muslim Council of Britain
- Muslim Health Network
- NAM Publications
- National Kidney Federation (UK)
- Neurological Alliance
- Neurosupport
- Rarer Cancers Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Surya Foundation
- Tenovus
- Terrence Higgins Trust

Professional groups

- Association of British Clinical Diabetologists
- Association of Cancer Physicians
- Association of Diabetes Specialist Nurses
- Association of Renal Industries
- Association of Renal Technologists
- Association of Respiratory Nurse Specialists
- British Association for Nursing in Cardiac Care
- British Association for Services to the Elderly

- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research

Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

- tbc

Associated Public Health Groups

- tbc

- | | |
|--|--|
| <ul style="list-style-type: none">• British Association of Paediatric Nephrology• British Association of Urological Nurses• British Association of Urological Surgeons• British Cardiac Intervention Society• British Cardiovascular Society• British Diabetic Association• British Geriatrics Society• British Heart Foundation• British HIV Association• British Psychosocial Oncology Society (BPOS)• British Renal Society• British Society for Human Genetics• British Society for Paediatric Endocrinology & Diabetes• British Transplantation Society• British Urological Foundation• Cancer Networks Pharmacists Forum• Cancer Research UK• Diabetes Monitoring Forum• Diabetes Specialist Nurses• Faculty of Public Health Medicine• Health Protection Agency• National Diabetes Nurse Consultant Group• National Heart Forum (UK)• National Kidney Research Fund• Primary Care Cardiovascular Society• Primary Care Diabetes Society• Primary Care Respiratory Society UK• Renal Association• Renal Pharmacists Group• Royal College of General Practitioners | |
|--|--|

- | | |
|--|--|
| <ul style="list-style-type: none">• Royal College of Pathologists• Royal Pharmaceutical Society• Royal Society of Medicine• Royal Society of Public Health• Society for DGH Nephrologists• Society of Endocrinology• United Kingdom Clinical Pharmacy Association• United Kingdom Oncology Nursing Society• Vascular Society | |
|--|--|

Others

- NHS Bromley
- NHS Redbridge
- Welsh Government

GE paper sign-off: Elisabeth George, Associate Director Appraisals

Contributors to this paper:

Technical Lead: Richard A. Diaz

Project Manager: Andrew Kenyon

03 11 11